We are a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor, ME-344, a novel mitochondrial inhibitor, and PWT143, a highly selective PI3K delta inhibitor.
[ Read more ]
MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at ASH [ October 6, 2015 ]
MEI Pharma Reports Fiscal Year 2015 Results [ September 2, 2015 ]
Click here for our 2014 Annual Review